The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Open-label, randomized, multicenter, phase II trial designed to compare the efficacy of CAPTEM combination versus FOLFIRI as second line treatment in patients (pts) who have progressed on or after first-line oxaliplatin-containing chemotherapy for advanced, MGMT methylated, RAS mutated colorectal cancer (CRC).
 
Rosa Berenato
No Relationships to Disclose
 
Filippo Pietrantonio
No Relationships to Disclose
 
Marta Caporale
No Relationships to Disclose
 
Ilaria Bossi
No Relationships to Disclose
 
Gianluca Tomasello
No Relationships to Disclose
 
Stefania Mosconi
No Relationships to Disclose
 
Emanuela Paterno
No Relationships to Disclose
 
Silvia Bozzarelli
No Relationships to Disclose
 
Raffaella Longarini
No Relationships to Disclose
 
Stefania Gori
No Relationships to Disclose
 
Alberto Zaniboni
No Relationships to Disclose
 
Alessandro Stefano Bertolini
No Relationships to Disclose
 
Francesca Bergamo
No Relationships to Disclose
 
Sandro Barni
No Relationships to Disclose
 
Alessio Amatu
Consulting or Advisory Role - Amgen; Lilly
Travel, Accommodations, Expenses - Amgen; Roche
 
Daniele Fagnani
No Relationships to Disclose
 
M. Giulia Zampino
No Relationships to Disclose
 
Federica Morano
No Relationships to Disclose
 
Maria Di Bartolomeo
No Relationships to Disclose
 
Filippo G. De Braud
No Relationships to Disclose